Document is current
Any future updates will be listed below
-
Authors
Sanvito, Francesco https://orcid.org/0000-0003-3379-9958
Yao, Jingwen
Nocera, Gianluca
Shao, Guowen
Wang, Zexi
Cho, Nicholas S.
Teraishi, Ashley
Raymond, Catalina
Patel, Kunal
Pouratian, Nader
Everson, Richard G.
Yang, Isaac
Salamon, Noriko
Kim, Won
Ellingson, Benjamin M.
-
Funding
Funding for this research was provided by:
University of California, Los Angeles (P50 CA211015)
Foundation for the National Institutes of Health (R01CA270027, R01CA279984, P50CA211015, F30CA28480, T32GM008042, T32GM152342)
- License Information
-
More Information
Article History
Received: 25 October 2024
Revised: 31 January 2025
Accepted: 6 March 2025
First Online: 18 April 2025
Compliance with ethical standards
:
: The scientific guarantor of this publication is Benjamin M. Ellingson.
: The authors of this manuscript declare relationships with the following companies: B.M.E. is on the advisory board and is a paid consultant for Medicenna, MedQIA, Servier Pharmaceuticals, Siemens, Janssen Pharmaceuticals, Imaging Endpoints, Kazia, Chimerix, Sumitomo Dainippon Pharma Oncology, ImmunoGenesis, Ellipses Pharma, Monteris, Neosoma, Alpheus Medical, Sagimet Biosciences, Sapience Therapeutics, Orbus Therapeutics, and the Global Coalition for Adaptive Research (GCAR). W.K. is a consultant for Monteris Medical. N.S.C. discloses a provisional patent (US 63/570,544) unrelated to current work. The remaining authors declare no conflicts of interest.
: Many authors have significant statistical expertise, in particular. Benjamin M. Ellingson supervised the mathematical modeling.
: Written informed consent was obtained from all subjects (patients) in this study.
: Institutional Review Board approval was obtained (IRB-21-1070).
: Some study subjects or cohorts have been previously reported in Sanvito et al []. Note that the aim and findings of the present article are substantially different from the previously published study.
:
